Sam S Yoon1, Thomas A Aloia2, Alex B Haynes2, Avinash Kambadakone3, Harmeet Kaur4, Jean-Nicolas Vauthey2, Cristina R Ferrone5, Andrew X Zhu6, Jennifer Y Wo7, Christopher Crane8, Theodore S Hong7. 1. Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: yoons@mskcc.org. 2. Department of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 4. Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 6. Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 7. Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 8. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
PURPOSE: Delivery of radiation therapy (RT) to unresectable liver tumors is sometimes limited by proximity of radiosensitive bowel. We sought to determine if biologic mesh spacers (BMS) could be used in this situation. METHODS AND MATERIALS: BMS composed of acellular human dermis were placed via a laparoscopic or open approach to displace bowel away from unresectable liver tumors in patients previously unable to receive radiation therapy (RT) due to risk of bowel toxicity. RESULTS: In 1 year, 14 patients were treated. Median age was 64 years. Diagnoses included intrahepatic cholangiocarcinoma (n = 6), hepatocellular carcinoma (n = 3), and metastases (n = 5). A solitary lesion was present in 8 patients, while 4 patients had 2 lesions and 2 patients had 3 lesions. Median largest tumor size was 6.3 cm (range, 1.6-17.5 cm). Limited extrahepatic disease was present in 5 patients. The surgical approach was laparoscopic in 10 patients and open in 4 patients. Median length of stay was 2.5 days (1-8), and 3 patients developed low-grade complications. Folded, extra thick (2.3-3.3 mm) BMS, with a median area of 384 cm(2) (256-640 cm(2)), were used to displace stomach (n = 9), duodenum (7), colon (6), and small bowel (2). The mean displacement of these organs on postprocedure imaging was 23 mm, 23 mm, 24 mm, and 20 mm, respectively. Two patients did not receive RT due to extrahepatic disease progression. The remaining patients had 3-dimensional conformal proton RT (n = 5), stereotactic body RT (4), or intensity modulated RT (3). Median dose delivered was 54 Gy (40-58.5) in 5-15 fractions with only 1 patient with grade 3-4 toxicity. At short-term follow-up of at least 10 months, local disease control was obtained in 11 of 12 patients. CONCLUSIONS: Initial dual institution experience with this novel strategy demonstrates feasibility, allowing previously untreatable liver tumor patients to receive high-dose RT.
PURPOSE: Delivery of radiation therapy (RT) to unresectable liver tumors is sometimes limited by proximity of radiosensitive bowel. We sought to determine if biologic mesh spacers (BMS) could be used in this situation. METHODS AND MATERIALS: BMS composed of acellular human dermis were placed via a laparoscopic or open approach to displace bowel away from unresectable liver tumors in patients previously unable to receive radiation therapy (RT) due to risk of bowel toxicity. RESULTS: In 1 year, 14 patients were treated. Median age was 64 years. Diagnoses included intrahepatic cholangiocarcinoma (n = 6), hepatocellular carcinoma (n = 3), and metastases (n = 5). A solitary lesion was present in 8 patients, while 4 patients had 2 lesions and 2 patients had 3 lesions. Median largest tumor size was 6.3 cm (range, 1.6-17.5 cm). Limited extrahepatic disease was present in 5 patients. The surgical approach was laparoscopic in 10 patients and open in 4 patients. Median length of stay was 2.5 days (1-8), and 3 patients developed low-grade complications. Folded, extra thick (2.3-3.3 mm) BMS, with a median area of 384 cm(2) (256-640 cm(2)), were used to displace stomach (n = 9), duodenum (7), colon (6), and small bowel (2). The mean displacement of these organs on postprocedure imaging was 23 mm, 23 mm, 24 mm, and 20 mm, respectively. Two patients did not receive RT due to extrahepatic disease progression. The remaining patients had 3-dimensional conformal proton RT (n = 5), stereotactic body RT (4), or intensity modulated RT (3). Median dose delivered was 54 Gy (40-58.5) in 5-15 fractions with only 1 patient with grade 3-4 toxicity. At short-term follow-up of at least 10 months, local disease control was obtained in 11 of 12 patients. CONCLUSIONS: Initial dual institution experience with this novel strategy demonstrates feasibility, allowing previously untreatable liver tumorpatients to receive high-dose RT.
Authors: Morten Høyer; Anand Swaminath; Sean Bydder; Michael Lock; Alejandra Méndez Romero; Brian Kavanagh; Karyn A Goodman; Paul Okunieff; Laura A Dawson Journal: Int J Radiat Oncol Biol Phys Date: 2012-03-01 Impact factor: 7.038
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Kimberly L Shampain; Caitlin E Hackett; Sohrab Towfighi; Anum Aslam; William R Masch; Alison C Harris; Silvia D Chang; Kanika Khanna; Vivek Mendiratta; Ahmed M Gabr; Dawn Owen; Mishal Mendiratta-Lala Journal: Abdom Radiol (NY) Date: 2021-05-07
Authors: Laura A Dawson; Kathryn A Winter; Alan W Katz; Michael C Schell; James Brierley; Yuhchyau Chen; Neil Kopek; Christopher H Crane; Christopher G Willett Journal: Pract Radiat Oncol Date: 2019-02-27
Authors: Theodore S Hong; Thomas F DeLaney; Harvey J Mamon; Christopher G Willett; Beow Y Yeap; Andrzej Niemierko; John A Wolfgang; Hsiao-Ming Lu; Judith Adams; Elizabeth A Weyman; Ronald S Arellano; Lawrence S Blaszkowsky; Jill N Allen; Kenneth K Tanabe; David P Ryan; Andrew X Zhu Journal: Pract Radiat Oncol Date: 2013-11-22